Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Climb Bio, Inc. - Common Stock (NQ:CLYM)

2.000 -0.050 (-2.44%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Climb Bio, Inc. - Common Stock

< Previous 1 2 Next >
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy
From Climb Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025
From Climb Bio, Inc.
Via GlobeNewswire
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
 
Via Benzinga
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025
From Climb Bio, Inc.
Via GlobeNewswire
UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming September 2025 Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Which stocks are moving after the closing bell on Friday?
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
Top movers in Thursday's after hours session
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Friday's after hours session: top gainers and losers
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors
Appointments Include Industry Veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors 
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at Upcoming Investor Conferences
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Climb Bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio to be Added to the Nasdaq Biotechnology Index
From Climb Bio, Inc.
Via GlobeNewswire
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
From Climb Bio, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.